Key result
LAAC carries ~2.5-fold higher systemic thromboembolism risk than DOACs despite reducing bleeding.
Why the study?
Left atrial appendage closure is a selective alternative to long-term oral anticoagulation in non-valvular high-risk AF, but individual contemporary RCTs remain underpowered to detect infrequent, clinically important outcomes.
Does left atrial appendage closure improve clinical and safety outcomes compared to direct oral anticoagulants in patients with non-valvular high-risk atrial fibrillation?
Meta-Analysis (n=6,239)
1:1 non-inferiority design (in the 5 included RCTs)
Does left atrial appendage closure improve clinical and safety outcomes compared to direct oral anticoagulants in patients with non-valvular high-risk atrial fibrillation?
Answers are grounded in this paper and cite their sources.
Compared with DOACs in high-risk non-valvular AF, LAAC offers similar mortality and overall stroke rates with lower nonprocedural bleeding, but carries higher risks of systemic thromboembolism, pericardial effusion, and serious adverse events, supporting phenotype-specific patient selection rather than routine substitution.
Introduction Left atrial appendage closure (LAAC) has emerged as a selective alternative to long-term oral anticoagulation in appropriately selected patients with non-valvular high-risk atrial fibrillation (AF). However, individual contemporary RCTs remain underpowered to detect infrequent but clinically important outcomes. Methodology This meta-analysis was prospectively registered in PROSPERO (CRD420261384938). A systematic literature search was conducted to identify RCTs comparing LAAC with direct oral anticoagulants (DOACs) therapy in patients with non-valvular high-risk AF. Statistical analyses were performed using R, with a two-sided significance threshold of p < 0.05. Results Five RCTs (n = 6,239; LAAC: 3,126; DOACs: 3,113) with 1:1 non-inferiority design were included. There were no significant differences between LAAC and DOACs for the composite endpoint, all-cause mortality or stroke. Systemic thromboembolism was significantly higher with LAAC (RR 2.53, 95% CI 1.04–6.19; p = 0.04; I² = 28.9%). LAAC was associated with significantly lower rates of minor bleeding (RR 0.48, 95% CI 0.40–0.58; p < 0.01; I² = 6.9%) and nonprocedural clinically relevant bleeding (RR 0.56, 95% CI 0.48–0.65; p < 0.01; I² = 0.0%). Pericardial effusion was significantly higher with LAAC (RR 2.35, 95% CI 1.15–4.83; p = 0.02; I² = 0.0%). Serious adverse events were modestly but significantly higher in the LAAC group (RR 1.08, 95% CI 1.02–1.14). Conclusion In contemporary randomized trials, LAAC and DOAC-based therapy showed no significant differences in mortality or overall stroke outcomes but demonstrated divergent safety tradeoffs. LAAC was associated with less nonprocedural clinically relevant bleeding, while systemic thromboembolism, pericardial effusion, and serious adverse events occurred more frequently with device-based therapy. These findings support phenotype-specific selection of LAAC rather than routine substitution for evidence-based anticoagulation.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2026) conducted a meta-analysis in Non-valvular high-risk atrial fibrillation (n=6,239). Left atrial appendage closure (LAAC) vs. Direct oral anticoagulants (DOACs) was evaluated on Systemic thromboembolism, nonprocedural clinically relevant bleeding, composite endpoint, all-cause mortality, and stroke (RR 2.53, 95% CI 1.04-6.19, p=0.04). LAAC vs DOACs lowered clinically relevant bleeding but increased systemic thromboembolism, with similar mortality and stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: